Home
/
Akebia Therapeutics, Inc.
/
Financials
/
Quarterly
Akebia Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Akebia Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2016
Sep 30, 2016
$0
Nov 9, 2016
Q2
2016
Jun 30, 2016
$0
Aug 8, 2016
Q1
2016
Mar 31, 2016
$0
May 5, 2016
Q3
2015
Sep 30, 2015
$0
Nov 9, 2015
Q2
2015
Jun 30, 2015
$0
Aug 11, 2015
Q1
2015
Mar 31, 2015
$0
May 11, 2015
Q3
2014
Sep 30, 2014
$0
Nov 10, 2014
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$58.77M
Nov 10, 2025
Q2
2025
Jun 30, 2025
$62.47M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$57.34M
May 8, 2025
Q3
2025
Sep 30, 2024
$37.43M
Nov 10, 2025
Q2
2025
Jun 30, 2024
$43.65M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$32.61M
May 8, 2025
Q3
2024
Sep 30, 2023
$42.05M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$56.38M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$40.01M
May 9, 2024
Q3
2023
Sep 30, 2022
$48.71M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$126.37M
Aug 28, 2023
Q1
2023
Mar 31, 2022
$61.70M
May 8, 2023
Q3
2022
Sep 30, 2021
$48.76M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$52.91M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$52.30M
May 9, 2022
Q3
2021
Sep 30, 2020
$59.99M
Nov 4, 2021
Q2
2021
Jun 30, 2020
$90.14M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$88.48M
May 10, 2021
Q3
2020
Sep 30, 2019
$91.98M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$100.80M
Aug 10, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$540.0K
Nov 10, 2025
Q3
2025
Jun 30, 2025
$247.0K
Nov 10, 2025
Q2
2025
Jun 30, 2025
$247.0K
Aug 7, 2025
Q3
2025
Mar 31, 2025
$6.11M
Nov 10, 2025
Q1
2025
Mar 31, 2025
$6.11M
May 8, 2025
Q2
2025
Mar 31, 2025
$6.11M
Aug 7, 2025
Q3
2025
Sep 30, 2024
($20.04M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($8.58M)
Aug 7, 2025
Q3
2025
Jun 30, 2024
($8.58M)
Nov 10, 2025
Q3
2025
Mar 31, 2024
($17.99M)
Nov 10, 2025
Q2
2025
Mar 31, 2024
($17.99M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($17.99M)
May 8, 2025
Q3
2024
Sep 30, 2023
($14.49M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($11.17M)
Aug 8, 2024
Q3
2024
Jun 30, 2023
($11.17M)
Nov 7, 2024
Q1
2024
Mar 31, 2023
($26.88M)
May 9, 2024
Q2
2024
Mar 31, 2023
($26.88M)
Aug 8, 2024
Q3
2024
Mar 31, 2023
($26.88M)
Nov 7, 2024
Q3
2023
Sep 30, 2022
($54.10M)
Nov 8, 2023
Q3
2023
Jun 30, 2022
$29.45M
Nov 8, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$4.45M
Nov 10, 2025
Q2
2025
Jun 30, 2025
$14.09M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$13.51M
May 8, 2025
Q3
2025
Sep 30, 2024
($12.51M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($8.73M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($14.94M)
May 8, 2025
Q3
2024
Sep 30, 2023
($13.04M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($9.00M)
Aug 8, 2024
Q2
2023
Mar 31, 2023
($25.60M)
Aug 28, 2023
Q1
2024
Mar 31, 2023
($25.60M)
May 9, 2024
Q3
2023
Sep 30, 2022
($50.41M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
$34.08M
Aug 28, 2023
Q2
2023
Mar 31, 2022
($59.58M)
Aug 28, 2023
Q1
2023
Mar 31, 2022
($58.49M)
May 8, 2023
Q3
2022
Sep 30, 2021
($54.89M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($79.34M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($64.94M)
May 9, 2022
Q3
2021
Sep 30, 2020
($58.10M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($173.82M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($59.13M)
May 10, 2021